Recent Updates
Recently added Catalysts

Diclofenac, 1%

Phase 3

Osteoarthritis | Small molecule | Musculoskeletal |Amneal Pharmaceuticals, Inc.|Last Updated: Jun 16, 2021

Target and mechanism

ModalitySmall molecule

Also known as Diclofenac Sodium Topical Gel, 1%

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLEDDMC
Total Trials1
Total Enrollment1,176

FDA Designations

No designations recorded

Clinical trial landscape

Diclofenac, 1% · 1 trial · 1 indication

Phase 3 1
NCT02121002Study Comparing a Generic Diclofenac Sodium Topical Gel, 1% to Voltaren in the Treatment of Subjects With Osteoarthritis of the KneeOsteoarthritis
COMPLETED1,176 Analytics
PHASE3COMPLETED
Study Comparing a Generic Diclofenac Sodium Topical Gel, 1% to Voltaren in the Treatment of Subjects With Osteoarthritis of the Knee
OsteoarthritisUnlock trial analytics

Study Endpoints

Primary Endpoints

Change From Baseline to 4 Weeks in WOMAC Pain Score
Baseline and Week 4

Mean change from baseline to week 4 in the Western Ontario McMaster Osteoarthritis (WOMAC) pain score: 5-point Likert scale: none=o, mild=1, moderate=2, severe=3, extreme=4

Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Diclofenac Sodium Topical Gel, 1%EXPERIMENTALDiclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks
Voltaren Topical Gel, 1%ACTIVE_COMPARATORVoltaren Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks
Vehicle Diclofenac Sodium Topical GelPLACEBO_COMPARATORVehicle Diclofenac Sodium Topical Gel. 4 gm, 4 times a day for 4 weeks

Interventions

NameTypeDescription
Diclofenac Sodium Topical Gel, 1%DRUGOpaque, white gel
Voltaren Topical Gel, 1%DRUGOpaque, white gel
Vehicle Diclofenac Sodium Topical GelDRUGOpaque, white gel
Unlock Study Design Details

Eligibility Criteria

Age Range35 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites22

Inclusion Criteria: * Healthy, ambulatory male or non-pregnant female subjects aged ≥ 35 years with a clinical diagnosis of OA of the knee. * Had an X-ray of the target knee, taken no more than 1 year before baseline, showing evidence of OA with Kellgren-Lawrence grade 1-3 disease. * After disconti...

Countries:India
Unlock Eligibility Criteria